Trial Profile
Efficacy and Safety of Anlotinib Versus Docetaxel in Advanced Non-squamous Non-small-cell Lung Cancer Without EGFR Mutation Who Failed in First-line Platinum-based Doublet Chemotherapy: an Open, Muti-center, Randomized Controlled Trial
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer
- 16 Oct 2018 New trial record